T 0699/19 (Anti-NGF antibodies/RINAT) of 05.04.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T069919.20220405
- Date of decision
- 5 April 2022
- Case number
- T 0699/19
- Petition for review of
- -
- Application number
- 10176627.7
- IPC class
- A61P 25/04A61K 39/395C07K 16/22
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Anti-NGF antibodies and methods using same
- Applicant name
- Rinat Neuroscience Corp.
- Opponent name
- Regeneron Pharmaceuticals, Inc.
Nexvet Australia Pty Ltd (opposition withdrawn)
James Poole Limited
Teva Pharmaceutical Industries, Ltd. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(c)European Patent Convention Art 123(2)European Patent Convention Art 54(3)European Patent Convention Art 76(1)European Patent Convention Art 84European Patent Convention Art 87(1)
- Keywords
- Priority - basis in priority document (no)
Claims - clarity after amendment (no)
Novelty - enabling disclosure
Grounds for opposition - subject-matter extends beyond content of earlier application (yes)
Divisional application - subject-matter extends beyond content of earlier application (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent with the following claims and the description and drawings to be adapted thereto, if need be:
Claims 1 to 10 of auxiliary request 20 filed with the statement of grounds of appeal.
3. The appeal fee is to be reimbursed to the intervener.